Core Insights - Upstream Bio announced positive results from the Phase 2 VALIANT trial for verekitug, showing significant reductions in asthma exacerbation rates and improvements in lung function [2][3][4] Efficacy and Safety - Verekitug demonstrated a 56% reduction in annualized asthma exacerbation rate (AAER) at a dose of 100 mg every 12 weeks and a 39% reduction at 400 mg every 24 weeks compared to placebo [3] - Improvements in lung function were observed, with a placebo-adjusted increase in forced expiratory volume in one second (FEV1) of 122 mL for the 100 mg q12w group and 139 mL for the 400 mg q24w group [4] - The drug also significantly suppressed exhaled nitric oxide (FeNO), with reductions of 20.4 ppb and 26.3 ppb for the respective dosing regimens [4] Patient Enrollment and Future Trials - Over 90% of eligible patients from the VALIANT trial have transitioned to the Phase 2 VALOUR long-term extension study [8] - Upstream Bio plans to advance verekitug into Phase 3 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) following regulatory interactions [6][9] Company Overview - Upstream Bio is focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, and is advancing verekitug as a unique antagonist targeting the TSLP receptor [19][12] - The company has conducted multiple Phase 2 trials for verekitug, including studies for chronic obstructive pulmonary disease (COPD) and CRSwNP, and is committed to addressing unmet needs in severe asthma treatment [18][19]
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma